In 2023, Swiss health insurance companies spent a record CHF9 billion ($10.2 billion) on medicines, marking a nearly 6% increase from the previous year. Factors driving this rise include an aging population, increased medication use per person, and the introduction of costly new therapies. Cancer and immune system drugs alone accounted for almost a third of total medication costs, while diabetes medication expenditures surged to CHF455 million, influenced by the high costs of new treatments like semaglutide.